Semaglutide oral pills: deciding whether the tablet route is right for you

How the oral route actually works day to day

The GLP-1 receptor agonist in the tablet is the same semaglutide found in the injection, but getting it through the gut wall requires a co-formulated absorption enhancer called SNAC. Absorption is sensitive to conditions in the stomach, which is why the timing rules are firm: the tablet goes in before anything else, with no more than a small sip of plain water, and you wait a full 30 minutes before your first coffee, breakfast or any other medication. For most people the easiest anchor is putting the tablet next to the kettle the night before so it is literally the first thing the hand reaches.

Because no refrigeration is needed, the tablets suit people whose lives make injectable storage difficult: frequent travel, shared accommodation, a job with unpredictable hours. If you are curious about how semaglutide pills compare across the different products currently available, that page sets out a useful overview of the format and what distinguishes each option. The oral semaglutide format removes the injection entirely, which matters to some people more than any clinical nuance.

One practical note worth knowing before you start: if you are already established on the 2.4 mg weekly injection at maintenance dose, a prescriber can assess whether you move directly to the 25 mg tablet rather than restarting the full titration from scratch. That transition still requires clinical sign-off; it is not automatic.

What the trial evidence says, and who it involved

The MHRA's approval rested on OASIS 4, a phase-three trial of 307 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants were also following lifestyle changes alongside the medicine. The headline result was an average loss of roughly 13.6% of body weight compared with around 2.4% on placebo. Among those who stayed fully adherent to treatment throughout, that figure was closer to 17%. The distinction matters: 17% is a real and meaningful number, but it describes the best-case group inside the trial, not everyone who starts the tablet.

For context, the 64-week injection data from STEP 1 showed approximately 15% average weight loss at the 2.4 mg injection dose, and longer trials at the newer 7.2 mg injection maintenance dose have approached 21%. You can read a fuller comparison of the evidence on the semaglutide tablets effectiveness page. The honest summary is that the tablet produces meaningful weight loss, somewhat less on average than the highest injection doses, in exchange for a format that is genuinely easier to live with for some people.

The most common side effects in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported in roughly 74% of the treatment group versus 42% of the placebo group. That sounds stark, but the majority were mild to moderate and tended to settle as the body adjusted to each dose level. Slower titration is one of the tools prescribers use if those effects are significant. The NHS patient-level guidance on semaglutide covers the full side-effect profile and signs that warrant medical attention.

Who the tablet is and is not licensed for

The UK licence for Wegovy tablets covers adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who have at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The tablet is not currently licensed for under-18s, and it is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive.

A separate oral semaglutide product, Rybelsus, exists at 3 mg, 7 mg and 14 mg strengths. Those strengths are licensed for type 2 diabetes, not weight management, and they form an entirely different prescribing pathway. If you have seen a page about 3 mg semaglutide pills, that is the diabetes context. The weight-loss tablet schedule (1.5 mg through to 25 mg) is specific to Wegovy tablets and the two should not be confused.

The MHRA approval also confirmed that Wegovy tablets are not yet available on the NHS: a separate NICE appraisal would be required before NHS commissioning could begin. For now, access is through private prescription only. If you want to understand the broader landscape of weight-loss treatment options in the UK, including what is and is not available through the NHS, that page brings together the current picture.

Making the decision: injection, tablet, or neither yet

The honest frame for this decision is not which format is objectively superior; it is which one fits your life, your medical history and what a prescriber judges appropriate for you. The injection produces somewhat greater average weight loss at the highest maintenance doses and has a longer evidence base. The tablet removes injection anxiety and refrigeration requirements entirely, and suits people who prefer a daily oral routine they can fit around other medicines.

Neither format is suitable for everyone, and the prescriber's job is precisely that assessment. Our clinical team at nume reviews every consultation personally on the day it is submitted. There is no algorithm making that call. If you want to read more about the tablet's specific profile before deciding, the Wegovy pill overview covers the licensing in more detail, and our FAQs answer the questions our prescribers hear most often from people weighing up the formats.

One last thing: if cost is part of your thinking, the where to buy Wegovy tablets in the UK page sets out the current private-market picture honestly, including what a legitimate price should and should not include. When you feel ready, check your eligibility with a free consultation and a prescriber will work through the rest with you.